Phase 3
Completed N=63
Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?
Source: ClinicalTrials.gov NCT00853073 ↗Enrolled (actual)
63
Serious AEs
0.0%
Results posted
Mar 2015
Primary outcomePrimary: Intraocular Pressure (IOP) — 11.52; 12.83 mmHg (millimeters of mercury)
Summary
The purpose of this study is to see if a new add on (or adjunctive) therapy used in glaucoma surgery improves the success of needle bleb revisions.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intraocular Pressure (IOP) |
11.52; 12.83 | — |
| SECONDARY Number of Participants With Surgical Success |
17; 12; 0; 2; 12; 15 | — |
Eligibility Criteria
Inclusion Criteria
- require glaucoma bleb needle revision with Mitomycin-C
Exclusion Criteria
- pregnant, nursing, or not using adequate contraception
- other glaucoma eye surgery involving tube shunts
- prior retinal detachments surgery with scleral buckle
- infection, inflammation, or any abnormality preventing eye pressure measurement
- enrolled in another investigational study
Data sourced from ClinicalTrials.gov (NCT00853073). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.